Analyst David Risinger reiterated Overweight rating and $217.00 price target.
https://www.streetinsider.com/Analyst+Comments/Eli+Lillys+%28LLY%29+Tirzepatide+%22Mega-blockbuster+Potential%22+is+Confirmed%2C+Morgan+Stanley+Reiterates+Overweight/18086651.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.